Company news
Starpharma Holdings Limited (ASX:SPL) news
Starpharma Holdings Limited news releases on 6ix. Latest, Sep 4, 2026: S&P DJI Announces September 2026 Quarterly Rebalance
Press releases & updates
S&P DJI Announces September 2026 Quarterly Rebalance
September 4, 2026
FY26 Key Financial Results and Annual Report
August 25, 2026
Successful Completion of $32 million Entitlement Offer
August 10, 2026
Entitlement Offer Investor Presentation
July 14, 2026
DEP milestone triggers partner option fee
July 2, 2026
Positive DEP HER2-Lu preclinical data support Phase 1 entry
July 1, 2026
FDA confirms path to DEP HER2 first-in-human study
April 21, 2026
Half Yearly Report and Accounts
February 17, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 28, 2026
AGM Chair address and CEO presentation
November 14, 2025
Upfront payment of USD $5.5 million received from Genentech
October 21, 2025
SPL:Research & Option Agreement with Radiopharm Theranostics
September 30, 2025
Starpharma Announces a Collaboration and License Agreement with Genentech
September 22, 2025
Presentation to Accompany License Agreement with Genentech
September 21, 2025
Starpharma Announces License Agreement with Genentech
September 21, 2025
$3.7M R&D Tax Incentive Received
August 27, 2025
FY25 Key Financial Results and Annual Report
August 26, 2025
2025 Appendix 4E Preliminary Financial Report
August 26, 2025
SPL receives positive FDA feedback on DEP SN38 for PROC
December 18, 2024
AGM Chair's address and CEO's presentation
November 26, 2024
SPL7013 Nasal Spray Australia Update
October 17, 2024
Starpharma Receives $5.5M R&D Tax Incentive Refund
September 11, 2024
Annual Report to shareholders
August 21, 2024
Positive final DEP irinotecan Phase 2 clinical trial results
May 27, 2024
Starpharma Business Update
May 22, 2024
Starpharma and Medicxi Partnership Petalion Therapeutics
April 7, 2024
S&P DJI Announces March 2024 Quarterly Rebalance
March 1, 2024
VivaGel BV US FDA Appeal Outcome
February 18, 2024
Viraleze shows antiviral efficacy in COVID-19 patients
January 28, 2024
VivaGel BV sales and distribution agreement MENA region
January 22, 2024
Positive DEP docetaxel Phase 2 results
December 18, 2023
AGM Chairman's address and CEO presentation
November 29, 2023
Starpharma announces new CEO, Ms Cheryl Maley
November 9, 2023
Starpharma receives $7.2 million R&D Tax Incentive refund
October 22, 2023
Positive DEP Cabazitaxel Phase 2 Results in Multiple Cancer
October 17, 2023
DEP irinotecan clinical data presented at AACR meeting
October 15, 2023
DEP irinotecan combination data presentation
September 26, 2023
VIRALEZ UK COVID-19 Clinical Study Completes Recruitment
September 25, 2023
Positive DEP irinotecan clinical results presentation
September 13, 2023
App 4E/Annual Report to shareholders
August 23, 2023
SPL to receive $6.5M from Mundipharma and VivaGel BV rights
August 13, 2023
Partnered Program Update
July 31, 2023
Trading Halt
July 28, 2023
Pause in Trading
July 28, 2023
Starpharma partners with UQ to advance DEP radio pipeline
July 25, 2023
DEP HER2-radiodiagnostic shows imaging benefits
July 20, 2023
Clinical Trial Update
June 27, 2023
Starpharma CEO to retire in 2024
June 8, 2023
VIRALEZE Nasal Spray Approved in Malaysia
June 5, 2023
HER2-targeted DEP SN38 ADC outperforms in HER2 cancer model
April 26, 2023